DEBINT4.GIF (10584 bytes)

DebRA International Current Research Projects      Research Report

DebRA Research

 

 

Assembly of Hemidesmosomes and Identification of Novel Hemidesmosomal Components

Name of Researchers: Dr Arnold Sonnenberg
Places of Research: The Netherlands Cancer Institute, Amsterdam
Approved by DebRA
Medical & Scientific Advisory Panel:
15 /06/1998
Budget approved by
DebRA central Committee:
11/07/ 1998
Date Commenced: 1st October 1998 - 3 years

 

SUMMARY OF RESEARCH BEING UNDERTAKEN

Epidermolysis Bullosa is a set of genetically inherited conditions affecting 1 in 17,000 of the population. A fault in a gene causes the skin to be extremely fragile. The layers of the skin do not adhere properly and painful widespread blisters occur very easily. These can lead to increasing disfigurement, disability and in the most severe forms death in early childhood.

The different forms of EB are caused by molecular abnormalities (mutations) in many genes encoding the proteins which provide the strength to hold the layers of the skin together at the junction between the dermis and the epidermis, called the cutaneous basement membrane.

Abstract of Research

This project aims to establish the protein-protein interactions that are involved in the assembly of hemidesmosomes. Genes encoding different components of hemidesmosomes have been found to be mutated in various forms of hereditary bullous skin disorders. Furthermore, these hemidesmosomal components often appeared to be targets for antibodies in acquired bullous pemphigoid autoimmune diseases. Knowledge about the protein-protein interactions is important because it gives essential information about how hemidesmosomes assemble and thus may help to explain the devastating effects of the absence of a single protein in this complex on the stability of the epidermal-dermal junctions. The results obtained may provide the basis for specific gene therapy experiments and will clarify whether abnormalities of other adhesion junctions may also be involved in such diseases.

The aim is to test the idea that the clinical condition might be greatly improved by reinforcing the fragile cell instead of repairing it. It should be possible to switch on an extra gene of related function by introducing a small molecule into the skin cells. Such therapy would be easier to deliver and could provide a strategy which is not mutation specific (ie have to be tailored for each individual), and is therefore much cheaper than conventional gene therapy approaches.

         


About DebRA | About EB | Management of EB | Research | News & Events | Resources |

DebRA House  13 Wellington Business Park, Dukes Ride, Crowthorne, Berkshire RG45 6LS
Telephone: +44 (0) 1344 771961  Fax: +44 (0) 1344 762661
DebRA is a registered charityRegistered in Austria ZVR No 932762489

© DebRA international all rights reserved 2002